Chlorpromazine-tadalafil interaction leading to refractory ischemic priapism and penile prosthesis implantation: a case report

Priapism represents a rare urological emergency characterized by persistent penile erection unrelated to sexual stimulation. Although chlorpromazine-induced priapism has been documented, the synergistic interaction with phosphodiesterase type 5 inhibitors resulting in refractory cases necessitating...

Full description

Saved in:
Bibliographic Details
Published inBasic and clinical andrology Vol. 35; no. 1; pp. 30 - 6
Main Authors Arici, Can, Basaranoglu, Mert, Cayan, Selahittin, Bozlu, Murat, Akbay, Erdem
Format Journal Article
LanguageEnglish
Published England BioMed Central 14.08.2025
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Priapism represents a rare urological emergency characterized by persistent penile erection unrelated to sexual stimulation. Although chlorpromazine-induced priapism has been documented, the synergistic interaction with phosphodiesterase type 5 inhibitors resulting in refractory cases necessitating penile prosthesis implantation constitutes a novel clinical scenario requiring comprehensive documentation. We report a 56-year-old male who developed refractory ischemic priapism following self-administration of oral chlorpromazine for hiccups, taken 24 h after tadalafil 20 mg for erectile dysfunction. The patient had previously experienced a transient priapism episode 10 years earlier following isolated chlorpromazine use, establishing chlorpromazine as the primary etiological agent. Despite comprehensive management including corporal aspiration, intracavernosal sympathomimetic injection, and distal T-shunt creation, the patient developed recurrent priapism requiring penile prosthesis implantation. This case demonstrates compelling evidence of a dangerous chlorpromazine-tadalafil interaction resulting in treatment-refractory priapism. The synergistic pharmacological effects of alpha-adrenergic blockade and phosphodiesterase type 5 inhibition created a severe clinical presentation necessitating immediate penile prosthesis implantation. Healthcare practitioners must recognize this potentially devastating drug interaction and implement preventive measures through comprehensive medication reconciliation and patient counseling.
AbstractList Priapism represents a rare urological emergency characterized by persistent penile erection unrelated to sexual stimulation. Although chlorpromazine-induced priapism has been documented, the synergistic interaction with phosphodiesterase type 5 inhibitors resulting in refractory cases necessitating penile prosthesis implantation constitutes a novel clinical scenario requiring comprehensive documentation.BACKGROUNDPriapism represents a rare urological emergency characterized by persistent penile erection unrelated to sexual stimulation. Although chlorpromazine-induced priapism has been documented, the synergistic interaction with phosphodiesterase type 5 inhibitors resulting in refractory cases necessitating penile prosthesis implantation constitutes a novel clinical scenario requiring comprehensive documentation.We report a 56-year-old male who developed refractory ischemic priapism following self-administration of oral chlorpromazine for hiccups, taken 24 h after tadalafil 20 mg for erectile dysfunction. The patient had previously experienced a transient priapism episode 10 years earlier following isolated chlorpromazine use, establishing chlorpromazine as the primary etiological agent. Despite comprehensive management including corporal aspiration, intracavernosal sympathomimetic injection, and distal T-shunt creation, the patient developed recurrent priapism requiring penile prosthesis implantation.CASE PRESENTATIONWe report a 56-year-old male who developed refractory ischemic priapism following self-administration of oral chlorpromazine for hiccups, taken 24 h after tadalafil 20 mg for erectile dysfunction. The patient had previously experienced a transient priapism episode 10 years earlier following isolated chlorpromazine use, establishing chlorpromazine as the primary etiological agent. Despite comprehensive management including corporal aspiration, intracavernosal sympathomimetic injection, and distal T-shunt creation, the patient developed recurrent priapism requiring penile prosthesis implantation.This case demonstrates compelling evidence of a dangerous chlorpromazine-tadalafil interaction resulting in treatment-refractory priapism. The synergistic pharmacological effects of alpha-adrenergic blockade and phosphodiesterase type 5 inhibition created a severe clinical presentation necessitating immediate penile prosthesis implantation. Healthcare practitioners must recognize this potentially devastating drug interaction and implement preventive measures through comprehensive medication reconciliation and patient counseling.CONCLUSIONSThis case demonstrates compelling evidence of a dangerous chlorpromazine-tadalafil interaction resulting in treatment-refractory priapism. The synergistic pharmacological effects of alpha-adrenergic blockade and phosphodiesterase type 5 inhibition created a severe clinical presentation necessitating immediate penile prosthesis implantation. Healthcare practitioners must recognize this potentially devastating drug interaction and implement preventive measures through comprehensive medication reconciliation and patient counseling.
Abstract Background Priapism represents a rare urological emergency characterized by persistent penile erection unrelated to sexual stimulation. Although chlorpromazine-induced priapism has been documented, the synergistic interaction with phosphodiesterase type 5 inhibitors resulting in refractory cases necessitating penile prosthesis implantation constitutes a novel clinical scenario requiring comprehensive documentation. Case presentation We report a 56-year-old male who developed refractory ischemic priapism following self-administration of oral chlorpromazine for hiccups, taken 24 h after tadalafil 20 mg for erectile dysfunction. The patient had previously experienced a transient priapism episode 10 years earlier following isolated chlorpromazine use, establishing chlorpromazine as the primary etiological agent. Despite comprehensive management including corporal aspiration, intracavernosal sympathomimetic injection, and distal T-shunt creation, the patient developed recurrent priapism requiring penile prosthesis implantation. Conclusions This case demonstrates compelling evidence of a dangerous chlorpromazine-tadalafil interaction resulting in treatment-refractory priapism. The synergistic pharmacological effects of alpha-adrenergic blockade and phosphodiesterase type 5 inhibition created a severe clinical presentation necessitating immediate penile prosthesis implantation. Healthcare practitioners must recognize this potentially devastating drug interaction and implement preventive measures through comprehensive medication reconciliation and patient counseling.
Priapism represents a rare urological emergency characterized by persistent penile erection unrelated to sexual stimulation. Although chlorpromazine-induced priapism has been documented, the synergistic interaction with phosphodiesterase type 5 inhibitors resulting in refractory cases necessitating penile prosthesis implantation constitutes a novel clinical scenario requiring comprehensive documentation. We report a 56-year-old male who developed refractory ischemic priapism following self-administration of oral chlorpromazine for hiccups, taken 24 h after tadalafil 20 mg for erectile dysfunction. The patient had previously experienced a transient priapism episode 10 years earlier following isolated chlorpromazine use, establishing chlorpromazine as the primary etiological agent. Despite comprehensive management including corporal aspiration, intracavernosal sympathomimetic injection, and distal T-shunt creation, the patient developed recurrent priapism requiring penile prosthesis implantation. This case demonstrates compelling evidence of a dangerous chlorpromazine-tadalafil interaction resulting in treatment-refractory priapism. The synergistic pharmacological effects of alpha-adrenergic blockade and phosphodiesterase type 5 inhibition created a severe clinical presentation necessitating immediate penile prosthesis implantation. Healthcare practitioners must recognize this potentially devastating drug interaction and implement preventive measures through comprehensive medication reconciliation and patient counseling.
ArticleNumber 30
Author Akbay, Erdem
Basaranoglu, Mert
Cayan, Selahittin
Bozlu, Murat
Arici, Can
Author_xml – sequence: 1
  givenname: Can
  orcidid: 0009-0000-8034-0571
  surname: Arici
  fullname: Arici, Can
– sequence: 2
  givenname: Mert
  orcidid: 0000-0002-9873-4920
  surname: Basaranoglu
  fullname: Basaranoglu, Mert
– sequence: 3
  givenname: Selahittin
  orcidid: 0000-0003-4784-2208
  surname: Cayan
  fullname: Cayan, Selahittin
– sequence: 4
  givenname: Murat
  orcidid: 0000-0002-8624-0149
  surname: Bozlu
  fullname: Bozlu, Murat
– sequence: 5
  givenname: Erdem
  orcidid: 0000-0001-7669-414X
  surname: Akbay
  fullname: Akbay, Erdem
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40804624$$D View this record in MEDLINE/PubMed
BookMark eNpVkk9v1DAQxS1UREvpF-CAfOQS8L8kNheEVrRUqsQFztZsPNl15djBzqItBz473m6pWl_GGj_9xnrzXpOTmCIS8pazD5zr7mPhouOsYaJtGBO9bvYvyJlgLW8UN-zkyf2UXJRyy-oxRjLNXpFTVYvqhDojf1fbkPKc0wR_fMRmAQcBRh-ojwtmGBafIg0IzscNXRLNOB66Kd9RX4YtTn6gc_Yw-zJRiI7OGH3A2ktl2WLxhfppDhAXOKA-UaADFKycOeXlDXk5Qih48VDPyc_Lrz9W35qb71fXqy83zaCY2jfaMGdaNRgmjWgBkYu1kKD1iN0opQSUoxgYKq64xH50wiDvULtes25spTwn10euS3Br638nyHc2gbf3jZQ3FvLih4BWo-46OXKoHNU5tV5L4apdnBnVox4r6_ORNe_WE7oB45IhPIM-f4l-azfpt-VCtnUfphLePxBy-rXDstipeomhuoRpV6wU0kjTGyWq9N3TYY9T_m-wCsRRMFTDS93Oo4Qze0iKPSbF1qTY-6TYvfwHy6Kzyg
Cites_doi 10.1111/andr.13740
10.1038/s41443-025-01078-7
10.1016/j.sxmr.2018.10.007
10.1248/bpb.b25-00083
10.1016/j.juro.2013.07.034
10.5534/wjmh.2016.34.1.1
10.1016/j.sxmr.2020.10.003
10.1038/s41443-022-00592-2
10.1155/2017/7394185
10.4088/PCC.19l02543
10.1093/sxmrev/qeae007
10.1097/JCP.0000000000001940
10.1038/ijir.2014.19
10.1038/s41443-022-00583-3
10.1007/s00120-016-0040-6
10.1016/s0361-1124(77)80171-8
10.1001/jama.2023.13377
10.1007/s13181-019-00719-w
ContentType Journal Article
Copyright 2025. The Author(s).
The Author(s) 2025 2025
Copyright_xml – notice: 2025. The Author(s).
– notice: The Author(s) 2025 2025
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.1186/s12610-025-00278-x
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Open Access Full Text
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 2051-4190
EndPage 6
ExternalDocumentID oai_doaj_org_article_8e8663f1ae7f46d4bb32d80410947e8f
PMC12351909
40804624
10_1186_s12610_025_00278_x
Genre Journal Article
GroupedDBID 0R~
53G
5VS
7X7
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABUWG
ACGFS
ADBBV
ADRAZ
ADUKV
AFKRA
AFPKN
AHBYD
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
DIK
EBLON
EBS
EMOBN
FYUFA
GROUPED_DOAJ
HMCUK
HYE
IAO
IHR
IHW
ITC
KQ8
M~E
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RBZ
ROL
RPM
RSV
SOJ
UKHRP
NPM
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c404x-890d954c903925aee12b23a88fe6f333ae3f2c0e41413e7fd29e16e8d7806f533
IEDL.DBID DOA
ISSN 2051-4190
IngestDate Wed Aug 27 01:31:23 EDT 2025
Thu Aug 21 18:25:34 EDT 2025
Thu Aug 14 17:50:38 EDT 2025
Sun Aug 17 02:22:25 EDT 2025
Thu Aug 21 00:03:59 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Penile prosthesis
Ischemic priapism
Priapism
Tadalafil
Drug interaction
Chlorpromazine
Language English
License 2025. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c404x-890d954c903925aee12b23a88fe6f333ae3f2c0e41413e7fd29e16e8d7806f533
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-8624-0149
0000-0001-7669-414X
0009-0000-8034-0571
0000-0003-4784-2208
0000-0002-9873-4920
OpenAccessLink https://doaj.org/article/8e8663f1ae7f46d4bb32d80410947e8f
PMID 40804624
PQID 3239397942
PQPubID 23479
PageCount 6
ParticipantIDs doaj_primary_oai_doaj_org_article_8e8663f1ae7f46d4bb32d80410947e8f
pubmedcentral_primary_oai_pubmedcentral_nih_gov_12351909
proquest_miscellaneous_3239397942
pubmed_primary_40804624
crossref_primary_10_1186_s12610_025_00278_x
PublicationCentury 2000
PublicationDate 20250814
PublicationDateYYYYMMDD 2025-08-14
PublicationDate_xml – month: 8
  year: 2025
  text: 20250814
  day: 14
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Basic and clinical andrology
PublicationTitleAlternate Basic Clin Androl
PublicationYear 2025
Publisher BioMed Central
BMC
Publisher_xml – name: BioMed Central
– name: BMC
References K Shigehara (278_CR3) 2016; 34
LP Ferreira (278_CR9) 2020; 22
N Schifano (278_CR18) 2024
N Schifano (278_CR5) 2024; 36
LC Licari (278_CR1) 2023; 13
H Ueda (278_CR15) 2023; 48
278_CR6
H Choi (278_CR14) 2015; 27
RJ Fantus (278_CR10) 2023; 330
E Zacharakis (278_CR17) 2014; 191
T Hwang (278_CR4) 2021; 9
NA Mistry (278_CR16) 2017; 2017
TE Merkin (278_CR7) 1977; 6
P Capogrosso (278_CR2) 2024; 36
M Capece (278_CR12) 2019; 7
F Inoue (278_CR8) 2023; 45
GA Beauchamp (278_CR13) 2019; 15
M Elmarasi (278_CR11) 2024; 12
References_xml – volume: 13
  start-page: 811
  issue: 4
  year: 2023
  ident: 278_CR1
  publication-title: Andrology
  doi: 10.1111/andr.13740
– year: 2024
  ident: 278_CR18
  publication-title: Int J Impot Res
  doi: 10.1038/s41443-025-01078-7
– volume: 7
  start-page: 530
  issue: 3
  year: 2019
  ident: 278_CR12
  publication-title: Sex Med Rev
  doi: 10.1016/j.sxmr.2018.10.007
– volume: 48
  start-page: 713
  issue: 5
  year: 2023
  ident: 278_CR15
  publication-title: Biol Pharm Bull
  doi: 10.1248/bpb.b25-00083
– volume: 191
  start-page: 164
  issue: 1
  year: 2014
  ident: 278_CR17
  publication-title: J Urol
  doi: 10.1016/j.juro.2013.07.034
– volume: 34
  start-page: 1
  issue: 1
  year: 2016
  ident: 278_CR3
  publication-title: World J Mens Health
  doi: 10.5534/wjmh.2016.34.1.1
– volume: 9
  start-page: 464
  issue: 3
  year: 2021
  ident: 278_CR4
  publication-title: Sex Med Rev
  doi: 10.1016/j.sxmr.2020.10.003
– volume: 36
  start-page: 6
  issue: 1
  year: 2024
  ident: 278_CR2
  publication-title: Int J Impot Res
  doi: 10.1038/s41443-022-00592-2
– volume: 2017
  start-page: 7394185
  year: 2017
  ident: 278_CR16
  publication-title: Case Rep Urol
  doi: 10.1155/2017/7394185
– volume: 22
  start-page: 19l02543
  issue: 4
  year: 2020
  ident: 278_CR9
  publication-title: Prim Care Companion CNS Disord
  doi: 10.4088/PCC.19l02543
– volume: 12
  start-page: 528
  issue: 3
  year: 2024
  ident: 278_CR11
  publication-title: Sex Med Rev
  doi: 10.1093/sxmrev/qeae007
– volume: 45
  start-page: 54
  issue: 1
  year: 2023
  ident: 278_CR8
  publication-title: J Clin Psychopharmacol
  doi: 10.1097/JCP.0000000000001940
– volume: 27
  start-page: 33
  issue: 1
  year: 2015
  ident: 278_CR14
  publication-title: Int J Impot Res
  doi: 10.1038/ijir.2014.19
– volume: 36
  start-page: 50
  issue: 1
  year: 2024
  ident: 278_CR5
  publication-title: Int J Impot Res
  doi: 10.1038/s41443-022-00583-3
– ident: 278_CR6
  doi: 10.1007/s00120-016-0040-6
– volume: 6
  start-page: 367
  issue: 8
  year: 1977
  ident: 278_CR7
  publication-title: JACEP
  doi: 10.1016/s0361-1124(77)80171-8
– volume: 330
  start-page: 559
  issue: 6
  year: 2023
  ident: 278_CR10
  publication-title: JAMA
  doi: 10.1001/jama.2023.13377
– volume: 15
  start-page: 262
  issue: 4
  year: 2019
  ident: 278_CR13
  publication-title: J Med Toxicol
  doi: 10.1007/s13181-019-00719-w
SSID ssj0000993080
Score 2.318236
Snippet Priapism represents a rare urological emergency characterized by persistent penile erection unrelated to sexual stimulation. Although chlorpromazine-induced...
Abstract Background Priapism represents a rare urological emergency characterized by persistent penile erection unrelated to sexual stimulation. Although...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 30
SubjectTerms Case Report
Chlorpromazine
Drug interaction
Ischemic priapism
Penile prosthesis
Priapism
Tadalafil
Title Chlorpromazine-tadalafil interaction leading to refractory ischemic priapism and penile prosthesis implantation: a case report
URI https://www.ncbi.nlm.nih.gov/pubmed/40804624
https://www.proquest.com/docview/3239397942
https://pubmed.ncbi.nlm.nih.gov/PMC12351909
https://doaj.org/article/8e8663f1ae7f46d4bb32d80410947e8f
Volume 35
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Pa9swFBZbd9llbOt-eN2CBmOXIWpLsiz31paWskMZY4XchGw9UY_EMXEK6WV_-56kpCRjsMuutkBC37Pe91lPnwj5VDiuaq0cC7mXSV14prVDzVPlTTBQQ9Ybq3yv1dWN_DotpztXfYWasGQPnCbuWIPGpOgLC5WXysmmEdwF0xzUJRVoH1ZfzHk7Yupn4j0CudD2lIxWx2OBWiFn4fbWuNvG1nuZKBr2_41l_lksuZN9Lp-TZxvaSE_TcF-QR9C_JIenPUrm-T39TGMhZ_xDfkh-nd-iCMcu5tE6mq2sszPruxkN3hDLdJKBzlL1PF0tKA5tGa_duacdit1QLk8HDMyhG-fU9o4O0OPigc8WI_LFsRtpNx9mNp1a6k-opS0mQ5r2H16Rm8uLH-dXbHPNAmtlLtdM17mrS9nWOeJVWoCCN1xYrT0oL4SwIDxvc5AFJjxEwfEaCgXaVTpXHunia3LQL3p4S2gjvJWuzUsOSgI2KFvRBsN3C7UQkGfky3bKzZDcNExUIVqZBJBBgEwEyKwzchZQeWgZnLDjA4wPs4kP86_4yMjHLaYGv5ywHWJ7WNyNRgT3txrXI56RNwnjh64kBo9UXGZE76G_N5b9N313G925w-FjZFn1u_8x-iPylMeQRakv35OD1fIOPiALWjUT8riaVhPy5Ozi-tv3SQz_37NhCWs
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Chlorpromazine-tadalafil+interaction+leading+to+refractory+ischemic+priapism+and+penile+prosthesis+implantation%3A+a+case+report&rft.jtitle=Basic+and+clinical+andrology&rft.au=Arici%2C+Can&rft.au=Basaranoglu%2C+Mert&rft.au=Cayan%2C+Selahittin&rft.au=Bozlu%2C+Murat&rft.date=2025-08-14&rft.issn=2051-4190&rft.eissn=2051-4190&rft.volume=35&rft.issue=1&rft_id=info:doi/10.1186%2Fs12610-025-00278-x&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12610_025_00278_x
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2051-4190&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2051-4190&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2051-4190&client=summon